Notice Type
Departmental
Consent to the Distribution of Changed Medicines Pursuant to section 24 (5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution inNew Zealand of the changed medicines set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Clarithromycin 125 mg/5 ml, 250 mg/5 ml Granules for oral suspension Abbott Laboratories Limited, Queenborough, Kent, Great Britain, Abbott Australasia Pty Limited, Kurnell, New South Wales, Australia and Abbott S.p.A., Campoverde de Aprilia, Latina, Italy Klacid Paediatric Suspension Clarithromycin 500 mg Powder for reconstitution for injection le laboratoire Abbott France, Usine de l'Isle, Saint-Remy-Sur-Avre, France Klacid I.V. Botulinium Toxin type A 100 units/vial Powder for reconstitution for IM injection Adria S P Inc., Albuquerque, New Mexico, United States of America Occulinum Injection Ondansetron (as the hydrochloride dihydrate) 4 mg, 8 mg Tablets Glaxo Operations UK Limited, Barnard Castle, County Durham, Great Britain and Glaxo Operations UK Limited, Ware, Hertfordshire, Great Britain Zofran Ondansetron (as the hydrochloride dihydrate) 4 mg/2 ml, 8 mg/4 ml Solution for IV and IM injection Glaxo Operations UK Limited, Barnard Castle, County Durham, Great Britain Zofran Injection Salmeterol (as xinafoate) 25 mcg Suspension (metered dose inhaler) Glaxo Group Research Limited, Ware, Hertfordshire, Great Britain, Laboratoires Glaxo SA, Evreux, France and Glaxo New Zealand Limited, Palmerston North Serevent Inhaler Salmeterol (as xinafoate) 50 mcg Rotadisks Glaxo Group Research Limited, Ware, Hertfordshire, Great Britain and Laboratoires Glaxo SA, Evreux, France Serevent Dated this 21st day of October 1993. C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.
Publication Date
28 Oct 1993

Notice Number

1993-go9114

Page Number

3201